Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies 52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Kahl, B., Roberts, A. W., Seymour, J. F., Advani, R. H., Persky, D. O., Yang, J., Cui, Y., Busman, T., Krivoshik, A., Enschede, S., Humerickhouse, R. AMER SOC HEMATOLOGY. 2010: 1608–
View details for Web of Science ID 000289662204363